Trial Profile
A Multicenter, Placebo Controlled, Randomized, Double Blind, Phase II Study to Evaluate the Efficacy and Safety of SJP002 Eye Drops in Patients With Dry Eye Syndrome.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Rebamipide (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Samjin Pharmaceutical Company
- 16 Mar 2022 Status changed from active, no longer recruiting to completed.
- 05 Nov 2018 New trial record